Teva Pharmaceutical Industries Limited and Alkermes plc: A Detailed Gross Profit Analysis

Teva vs. Alkermes: A Decade of Profit Shifts

__timestampAlkermes plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 201417091400011056000000
Thursday, January 1, 201514494200011356000000
Friday, January 1, 201622642400011859000000
Sunday, January 1, 201733573700010825000000
Monday, January 1, 20184924480008296000000
Tuesday, January 1, 20194777290007536000000
Wednesday, January 1, 20204658520007725000000
Friday, January 1, 20215698380007594000000
Saturday, January 1, 20228936870006973000000
Sunday, January 1, 202314103680007646000000
Monday, January 1, 202413123010008064000000
Loading chart...

Igniting the spark of knowledge

A Decade of Gross Profit Trends: Teva vs. Alkermes

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. Over the past decade, Teva Pharmaceutical Industries Limited and Alkermes plc have showcased contrasting gross profit trajectories. Teva, a giant in the industry, saw its gross profit peak in 2016, only to decline by approximately 41% by 2022. This decline reflects broader challenges in the generic drug market and increased competition. In contrast, Alkermes, a smaller player, demonstrated a remarkable growth trajectory, with its gross profit increasing by over 700% from 2014 to 2023. This growth underscores Alkermes' strategic focus on innovative therapies and niche markets. As of 2023, Alkermes' gross profit reached its highest, highlighting its resilience and strategic positioning. These trends offer a compelling narrative of adaptation and resilience in the face of industry challenges.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025